ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Pramipexole

Also written as “pramipexole”, “Pramipexole Dihydrochloride” and “Pramipexole Immediate Release”.

Its studies are mostly in Parkinson Disease · Restless Legs Syndrome · Tourette Syndrome · Depressive Disorder, Major · Obsessive-Compulsive Disorder, led by 6 companies.

Drug pagePramipexole: every studyMany companies study it; this page follows only the 43 they lead. All 81 studies, academic ones too, with its approvals and label.
Furthest: phase 4, since Sep 2, 200543 company-led studies, 1 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Boehringer Ingelheimits history only360 open or runningphase 4since Sep 2, 2005Aug 22, 2005none ahead
Teva Pharmaceutical Industries30 open or runningphase 4since Nov 10, 2006Nov 10, 2006none ahead
Chase Therapeuticsits history only11 open or runningphase 2since Jul 5, 2018Jul 5, 2018none ahead
GlaxoSmithKlineits history only10 open or runningphase 1since May 8, 2007May 8, 2007none ahead
Haisco Pharmaceutical Groupits history only10 open or runningphase 1since Apr 2, 2026Apr 2, 2026none ahead
Novartisits history only10 open or runningphase 4since Aug 23, 2012Aug 23, 2012none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Teva Pharmaceutical Industries only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Nov 10, 2006First study: phase 4 study in Parkinson DiseaseFirst studyNCT00399477 · 200 enrolled
  2. Feb 22, 20102 phase 1 studies in HealthyNCT01074463, NCT01074450

TargetBeta

“D2-like dopamine receptor agonist”ChEMBL 37, by rule

Other programs on the same three targets

ProgramCompanyFurthest phaseStudies
OlanzapineruleEli Lillyphase 476
rotigotineruleUCBphase 464

Studies

All 3 Teva Pharmaceutical Industries leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT01074463Healthy · United States1CompletedMar 200524
NCT01074450Healthy · United States1CompletedMar 200524
NCT00399477Parkinson Disease4CompletedJul 2007200

How it is read

Names in the registry

  • “Pramipexole”, 15 entries
  • “pramipexole”, 5 entries
  • “Pramipexole Dihydrochloride”, 4 entries
  • “Pramipexole Immediate Release”, 2 entries
  • “Pramipexole Extended Release”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.